Medical research, commercial
Shuttle Pharmaceuticals Holdings, Inc
Shuttle Pharmaceuticals Holdings, Inc., based in Gaithersburg, MD, is dedicated to developing innovative therapies aimed at increasing cancer cure rates, prolonging patient survival, and enhancing quality of life. Their lead drug candidate, Ropidoxuridine, is an orally available halogenated pyrimidine designed to sensitize cancer cells to radiation therapy while protecting healthy tissue.
The company is advancing a robust portfolio of patented selective histone deacetylase (HDAC) inhibitors and is focused on creating diagnostic blood tests for prostate cancer patients. Through strategic collaborations with academic institutions, Shuttle Pharmaceuticals aims to improve treatment outcomes by leveraging its drug discovery and proprietary diagnostic technologies. Generated from the website